Le Lézard
Classified in: Health
Subjects: NPT, TDS, DIS

Claire's Place Foundation Executive Director to Speak at BreatheCon 2023


Cystic Fibrosis Foundation selects Claire's Place Work Proudly Program for their BreatheCon Community Program Showcase

LOS ANGELES, Feb. 13, 2023 /PRNewswire-PRWeb/ -- Claire's Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to announce that their Work Proudly Program will be featured at the Cystic Fibrosis Foundation's BreatheCon 2023, February 23-25, 2023. Claire's Place Foundation Executive Director Melissa Yeager will present the purpose and success of the Work Proudly Program at the virtual event.

The seventh annual BreatheCon, hosted by the Cystic Fibrosis Foundation, is a unique online event for adults with CF to safely gather virtually. The event is an inclusive space to participate in timely discussions, affinity groups, creative activities and more.

A recipient of the CF Foundation's Impact Grant and Community Support Grant, the Claire's Place Work Proudly Program was chosen to be featured in BreatheCon's Community Program Showcase. The purpose of the Showcase is to highlight projects led by the CF community that support and empower people living with CF. The Claire's Place presentation will be on February 23rd at 5:30 pm PST.

The Claire's Place Work Proudly Program provides job training and equipment needed for work-from-home employment to adults with CF and caregivers. The program allows participants to gain the skills and access technology to be competitive in the job market and acquire flexible, work-from-home or hospital employment. Participants are recruited through a social worker referral.

"I am honored to be a presenter at BreatheCon 2023," said Claire's Place Foundation Executive Director Melissa Yeager. "We have been overwhelmed by the positive impact and demand for our Work Proudly Program since we launched it in 2020. I look forward to sharing success stories of our participants as well as answering questions and connecting with the BreatheCon attendees."

If you are an adult with CF and would like to attend BreatheCon 2023 visit here to register.

About Claire's Place Foundation, Inc.
Claire's Place Foundation, Inc. is a 501(c)(3) non-profit organization providing support to children and families affected by cystic fibrosis (CF). Claire's Place Foundation is named in honor of Claire Wineland who lived with CF her entire life and died at the age of 21. Claire was an activist, author, TEDx Speaker, social media star and received numerous awards. Claire's foundation was a way for her to assure that others living with CF enjoyed the same hope, strength and joy that she enjoyed. Recipient of Los Angeles Business Journal's "Small Nonprofit of the Year" and "Fundraiser of the Year'' for its annual Glow Ride, the foundation provides grants to families affected by CF, offering both emotional and financial support. Today, Claire's Place Foundation continues to carry on Claire's legacy. For more information and make a donation, please visit http://www.clairesplacefoundation.org.

Media Contact

Carrie Callahan, Claire's Place Foundation, 6174134589, [email protected]

 

SOURCE Claire's Place Foundation


These press releases may also interest you

at 03:05
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global...

at 03:05
Lantern Pharma Inc. , a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of...

at 03:00
Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light....

at 03:00
A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the...

at 02:11
Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and...

at 00:01
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and...



News published on and distributed by: